Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lucid Group Inc (LCID) vs Viatris Inc (VTRS) Price & Performance

Lucid Group IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Lucid Group Inc vs Viatris Inc — how do they compare? Lucid Group Inc trades at $3.79 (market cap $1.51B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 13.3× Lucid Group Inc's market cap, and Viatris Inc pays a 2.75% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and Viatris Inc for 57 Days on average.

LCIDVTRS
Market Cap
$1.51B$20.03B
Volume
12,333,74514,109,977
Sector
Consumer CyclicalHealth
52-Week High
$21.92$18.27
52-Week Low
$3.79$9.74
Typical Hold Time
45 Days57 Days
Enterprise Value
$4.40B$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lucid Group Inc

Lucid Group (LCID) trades at $3.82, down 1.8% with a bearish technical outlook. The company faces significant financial challenges with negative profit margins (-249.21% net income margin) and consecutive earnings misses. Recent developments include strategic partnerships for autonomous vehicles and software updates, but cash burn remains elevated at -$2.93B operating cash flow in 2025.

LCID presents high-risk turnaround potential with analyst consensus target of $7.60 (99% upside) but requires successful execution on cost savings and new vehicle launches. Key risks include persistent cash burn, production delays, and competitive EV market pressures. The stock's viability hinges on management's ability to achieve targeted $1.4B cost savings and deliver the delayed Cosmos SUV.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LCID
100% Buy0% Sell
Avg holding period · 45 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Lucid Group Inc

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.

Read more on LCID →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →